GHCM
BMRN icon

Glen Harbor Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Glen Harbor Capital Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-224
Closed -$20K – 1327
2019
Q1 		$20K Buy
+224
New +$20.8K ﹤0.01% 1275

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Glen Harbor Capital Management's BMRN Position: Q2 2019 in Review

Glen Harbor Capital Management sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2019, closing a stake of 224 shares — an estimated $20K sold.

Glen Harbor Capital Management first reported a position in BMRN in Q1 2019 and held it in 1 quarter. The position peaked at $20K in Q1 2019. 482 funds tracked by Wall St. Rank hold BMRN as of Q2 2019.

  • Glen Harbor Capital Management reported no remaining BioMarin Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • Glen Harbor Capital Management sold 224 BioMarin Pharmaceuticals shares in Q2 2019, an estimated $20K.
  • Glen Harbor Capital Management first reported a position in BioMarin Pharmaceuticals in Q1 2019 and held it in 1 quarter.
  • Glen Harbor Capital Management's BioMarin Pharmaceuticals position peaked at $20K in Q1 2019.
  • 482 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2019.

Based on Glen Harbor Capital Management's 13F filing for Q2 2019, filed 13 Aug 2019.